🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

ICU Medical, Inc. ICUI R2K

Healthcare · Medical Instruments & Supplies · United States
https://www.icumed.com

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

READ MORE ›
$135.39
+0.39% 1Y

Market & Price

Market Cap
$3.38B
Current Price
$135.39
High / Low (52W)
$158.54 / $108.10
Beta
0.74

Valuation

Stock P/E
73.18
Industry PE
23.65
Forward P/E
14.51
PEG Ratio
0.08
Book Value
$84.50
Price to Book
1.60
P/S
1.57
EV/EBITDA
14.24
Dividend Yield
-

Profitability & Returns

ROCE
2.75%
ROE
2.26%
ROA
1.68%
Profit Margin
2.15%
Op Margin
5.73%
EPS (Latest Qtr)
$1.20
EPS (TTM)
$1.85

Balance Sheet & Liquidity

Debt/Equity
0.64
Quick Ratio
0.95
Current Ratio
2.34
Debt
$1.34B
Total Assets
$4.05B
Current Assets
$1.19B
Working Capital
$691.69M

Ownership

Promoter Holding
3.80%
Chg in Prom Hold
-
FII / Inst Holding
113.71%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$4.43B
Total Revenue (TTM)
$2.16B
EBITDA
$311.45M
Free Cash Flow
$387.08M
Operating Cash Flow
$167.43M
Shares Outstanding
24.99M
Gross Margin
37.93%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-0.72%
Profit 5Y
33.66%
Revenue (YoY)
-12.30%
Earnings (YoY)
-

PROS

  • Profit CAGR of 33.7% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 73.2.
  • Revenue declined at -0.7% CAGR over 5 years.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ICUI ICU Medical, Inc. R2K 135.39 73.18 $3.38B - 2.75% 2.26% -0.72% 33.66%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ---------343.24M-372.03M360.46M327.17M-330.93M312.28M307.47M-328.61M303.38M318.57M-318.05M321.68M336.06M543.12M561.00M597.86M568.65M549.31M553.31M566.65M596.46M589.13M604.70M548.87M536.99M540.70M530.23M
Cost of Revenue -----------------------------------394.59M340.80M336.11M337.72M324.00M
Gross Profit 43.76M46.27M48.26M49.23M50.13M51.27M50.76M88.94M88.06M111.60M137.49M149.00M151.80M134.59M134.64M135.30M103.87M118.55M114.14M121.42M106.28M113.92M119.87M112.68M123.53M127.79M168.83M167.59M186.40M192.04M192.33M183.92M185.24M207.43M204.85M210.11M208.06M200.88M202.99M206.23M
Operating Expenses -----------------------------------180.52M181.26M174.02M176.90M175.85M
Operating Income 20.32M24.77M-23.95M22.77M22.45M--16.98M-35.93M-3.70M-4.91M31.72M2.25M-30.37M26.27M32.90M-26.06M19.56M25.53M-26.57M34.47M38.38M-42.16M-48.00K-467.00K9.39M2.76M22.85M-10.65M7.69M8.24M29.59M26.80M26.86M26.09M30.38M
EBITDA -----------------------------------63.80M106.41M70.52M57.71M64.56M
Interest Expense -----------------------------------25.26M23.07M22.23M22.78M18.53M
Pretax Income ------------------------------------10.91M33.68M-2.51M-15.90M-3.98M
Tax Provision -----------------------------------4.57M1.18M-658.00K-2.65M-34.71M
Net Income 13.57M16.27M5.46M18.16M16.61M18.81M9.51M55.86M-37.06M136.00K49.70M4.88M31.05M219.00K-7.36M31.00M22.83M26.56M20.64M16.83M18.91M24.99M26.14M23.73M28.40M31.08M-38.07M-7.47M-9.81M-9.81M-9.93M7.24M-39.47M-21.41M-32.98M-15.48M35.34M-3.40M-15.73M30.13M
Diluted EPS 0.830.980.331.080.981.090.542.86-1.870.012.330.231.440.01-0.361.441.061.240.960.780.881.161.211.091.311.43-1.61-0.31-0.55-0.41-0.410.30-1.63-0.88-1.35-0.631.43-0.14-0.641.20
R&D Expense 3.12M4.23M-3.31M3.34M3.65M-11.64M12.97M12.77M-12.59M13.57M13.18M-12.82M11.20M12.00M-10.75M10.28M10.13M-10.71M11.38M12.24M23.87M22.56M23.11M19.76M22.30M20.87M21.84M23.39M21.03M23.29M21.87M21.25M-21.28M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 188.14M204.73M228.97M282.96M302.19M316.87M313.72M309.26M341.67M379.37M1.29B1.40B1.27B1.27B-2.28B2.26B2.38B2.23B
Cost of Revenue ---------------1.58B1.52B1.56B1.41B
Gross Profit 78.24M89.82M106.28M128.97M142.35M156.51M154.73M151.40M180.80M201.40M426.10M570.03M471.86M461.50M-697.76M739.87M824.78M822.04M
Operating Expenses ---------------701.33M692.04M727.38M712.71M
Operating Income 24.65M31.38M35.43M47.66M65.22M61.28M51.95M39.04M68.56M82.94M-13.29M29.76M107.36M98.16M--3.57M47.84M97.41M109.33M
EBITDA ---------------191.55M253.20M260.04M298.44M
Interest Expense ---------------70.81M102.73M106.54M93.34M
Pretax Income ----------------114.41M-78.30M-66.01M4.36M
Tax Provision ----------------40.12M-48.64M51.68M2.44M
Net Income ---29.92M44.67M41.28M40.42M26.34M44.98M63.08M68.64M28.79M101.03M86.87M--74.29M-29.66M-117.69M732.00K
Diluted EPS 1.511.671.672.163.152.802.651.682.733.663.291.334.694.02--3.11-1.23-4.830.03
R&D Expense 8.11M4.82M2.65M4.68M8.59M10.63M12.41M18.33M15.71M12.96M51.25M52.87M48.61M42.95M47.50M92.98M85.34M88.61M87.50M

Compounded Sales Growth

5 Years:-0.72%
1 Year:-12.30%

Compounded Profit Growth

5 Years:33.66%
1 Year:-

Stock Price Performance

1 Year:+0.39%
6 Months:-10.87%
3 Months:-10.09%
1 Month:+17.27%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --283.43M309.15M309.64M361.11M428.51M499.64M541.10M626.83M704.69M1.50B1.59B1.69B1.76B-4.52B4.38B4.20B4.05B
Current Assets ----------------1.24B1.22B1.44B1.19B
Cash & Equivalents 13.15M7.87M55.70M51.25M78.85M99.59M146.90M226.02M275.81M336.16M445.08M290.07M344.78M268.67M396.10M-208.78M254.22M308.57M307.96M
Inventory ----------------696.01M709.36M584.68M615.86M
Receivables ----------------221.72M161.57M182.83M180.51M
Total Liabilities ----------------2.43B2.26B2.24B1.93B
Current Liabilities --21.96M33.70M25.76M29.31M29.12M26.89M28.73M42.62M40.54M210.29M249.29M248.47M195.49M-494.56M481.84M556.18M498.86M
Long Term Debt ----------------1.62B1.58B1.53B1.27B
Total Debt ----------------1.73B1.70B1.63B1.33B
Total Equity --253.03M263.43M271.70M320.58M390.86M464.73M508.25M579.87M660.15M1.20B1.26B1.38B1.50B-2.09B2.12B1.97B2.12B
Shares Outstanding ----------------23.99M24.14M24.52M24.69M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 41.51M30.32M51.14M33.09M64.49M66.27M65.73M66.34M64.19M89.94M154.42M160.22M101.92M222.75M--62.13M166.20M204.03M179.85M
Investing Cash Flow -10.30M3.51M-37.76M19.63M-45.73M-41.37M-13.12M-21.75M-11.24M16.28M-266.87M-103.37M-166.89M-98.14M--1.91B-87.95M-88.96M122.23M
Financing Cash Flow -36.96M13.98M-17.69M-22.88M2.13M21.63M24.39M13.65M15.68M2.47M-44.35M8.02M-10.91M-40.00K-1.64B-35.98M-55.80M-311.52M
Capital Expenditure -23.64M-11.35M-16.69M-23.17M-15.82M-19.16M-18.41M-16.60M-12.98M-23.36M-74.48M-92.72M-97.31M-92.00M--99.33M-93.67M-90.21M-97.02M
Free Cash Flow 17.87M18.97M34.45M9.92M48.66M47.11M47.31M49.74M51.21M66.58M79.94M67.50M4.61M130.75M--161.46M72.53M113.83M82.83M
Net Change in Cash ----------------334.56M42.27M59.27M-9.45M
Share Buybacks 41.00M5.86M20.44M28.65M11.96M03.03M5.84M1.52M17.23M4.06M6.25M18.64M12.88M8.34M10.88M9.35M11.99M8.77M

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 41.6%43.9%46.4%45.6%47.1%49.4%49.3%49.0%52.9%53.1%33.0%40.7%37.3%36.3%-30.6%32.8%34.6%36.8%
Operating Margin % 13.1%15.3%15.5%16.8%21.6%19.3%16.6%12.6%20.1%21.9%-1.0%2.1%8.5%7.7%--0.2%2.1%4.1%4.9%
Net Margin % ---10.6%14.8%13.0%12.9%8.5%13.2%16.6%5.3%2.1%8.0%6.8%--3.3%-1.3%-4.9%0.0%
ROE % ---11.0%13.9%10.6%8.7%5.2%7.8%9.6%5.7%2.3%7.3%5.8%--3.6%-1.4%-6.0%0.0%
ROCE % -12.0%12.9%16.8%19.7%15.3%11.0%7.6%11.7%12.5%-1.0%2.2%7.4%6.3%--0.1%1.2%2.7%3.1%

Shareholding Pattern

Insiders
3.80%
Institutions
113.71%
Public Float
118.20%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 14.44% 3.61M $488.53M
2 Janus Henderson Group PLC 10.71% 2.68M $362.31M
3 Vanguard Portfolio Management LLC 5.75% 1.44M $194.65M
4 Fuller & Thaler Asset Management Inc. 4.88% 1.22M $165.25M
5 Vanguard Capital Management LLC 4.45% 1.11M $150.54M
6 Dimensional Fund Advisors LP 3.94% 983.80K $133.20M
7 State Street Corporation 3.87% 968.05K $131.06M
8 Schroder Investment Management Group 2.81% 701.28K $94.95M
9 River Road Asset Management, LLC 2.59% 646.43K $87.52M
10 Geode Capital Management, LLC 2.45% 611.22K $82.75M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ICUI

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks